Forth Therapeutics launches with backing from Sofinnova Partners to revolutionize fibrosis treatments
- Cutting-edge research from Professor Neil Henderson at the University of Edinburgh
- Led by CEO Alex Leech, Partner at Sofinnova Partners
- Created through Sofinnova’s €165M Biovelocita II, biotech fund
EDINBURGH and CAMBRIDGE, UK – March 18, 2025 – Forth Therapeutics (Forth Tx), a biotechnology company advancing next-generation precision therapeutics for fibrosis, launches today with backing from Sofinnova Partners, a leading European life sciences venture capital firm, alongside Old College Capital (OCC), the University of Edinburgh’s in-house venture investment fund.
